What’s new
Oxford Cancer Biomarkers announces the EU patent for the use of the biomarker HR23B
Oxford, UK, 07 Sep 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be
Oxford Cancer Biomarkers announces funding has been awarded for a pilot study of the ColoTox test
Oxford, UK, 16th January 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be
Oxford Cancer Biomarkers announces biomarker discovery and development deal with Daiichi-Sankyo
Oxford, UK, 29th August 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be
Oxford Cancer Biomarkers announces issued United States patent
Oxford, UK, 24 July 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be
Oxford Cancer Biomarkers announces biomarker discovery deal with AstraZeneca
Oxford, UK, 15th April 2013 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be
Oxford Cancer Biomarkers appoints David Oxlade as its Chairman
Oxford, UK, 16 October 2013 Oxford Cancer Biomarkers has appointed David Oxlade as Chairman, a key growth milestone for the
Oxford Cancer Biomarkers appoints Nick McCooke as its CEO
Oxford Cancer Biomarkers has appointed Nick McCooke as CEO, a key growth milestone for the company which aims to benefit
Quintiles Forms New Biomarker Research and Development Company
Professors David Kerr and Nick La Thangue offer oncology consulting and biomarker R&D activities spun out from the University of